Glenmark Pharma Gains as US FDA Approves Acetaminophen and Ibuprofen Tablets

29 Apr 2024 , 01:04 PM

Glenmark Pharmaceuticals’ share price saw a slight increase in early trade on April 29 following the company’s receipt of final approval from the US FDA for acetaminophen and ibuprofen tablets.

At the time of writing, Glenmark Pharma was trading at ₹1,084.90 on the BSE, up by ₹5.55 or 0.51%. Over the past year, the stock has surged by 99.47%, and since the beginning of the year, it has increased by 26.79%. Glenmark’s share price hit a 52-week high of ₹1,095.95 and a low of ₹516.65 on April 25, 2024, and April 26, 2023, respectively. 

The company announced that it has received final approval from the USFDA for acetaminophen and ibuprofen tablets, 250 mg/125 mg (OTC), which are deemed bioequivalent to advil dual action with acetaminophen tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC.

Glenmark will distribute these tablets in the US through its subsidiary, Glenmark Therapeutics Inc, USA. Currently, Glenmark’s portfolio includes 195 products authorized for distribution in the US market, with 52 ANDAs pending approval from the USFDA.

The company also stated its ongoing efforts to seek external development partnerships to complement and accelerate the growth of its existing pipeline and portfolio.

For feedback and suggestions, write to us at [e-mail]